- Home
- ATO vs RPRX Comparison
ATO vs RPRX Comparison
Compare ATO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATO | RPRX |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8B | 25.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATO | RPRX |
|---|---|---|
| Price | $170.22 | $59.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $182.25 | $51.40 |
| AVG Volume (30 Days) | 918.4K | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.15% | 1.90% |
| EPS Growth | ★ 9.22 | N/A |
| EPS | ★ 7.33 | 0.71 |
| Revenue | ★ $4,702,755,000.00 | $2,378,193,000.00 |
| Revenue This Year | $15.32 | $38.63 |
| Revenue Next Year | $10.09 | $4.73 |
| P/E Ratio | ★ $23.18 | $82.54 |
| Revenue Growth | ★ 12.91 | 5.06 |
| 52 Week Low | $160.10 | $34.63 |
| 52 Week High | $192.51 | $60.44 |
Technical Indicators
Market Signals| Indicator | ATO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 57.96 |
| Support Level | $165.47 | $55.66 |
| Resistance Level | $171.21 | $60.44 |
| Average True Range (ATR) | 2.91 | 1.42 |
| MACD | -0.46 | -0.01 |
| Stochastic Oscillator | 20.07 | 69.85 |
Price Performance
Historical ComparisonAbout ATO Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.